Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

INVO Fertility (IVF) Receivables (2016 - 2025)

Historic Receivables for INVO Fertility (IVF) over the last 17 years, with Q3 2025 value amounting to $274200.0.

  • INVO Fertility's Receivables rose 667.14% to $274200.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $274200.0, marking a year-over-year increase of 667.14%. This contributed to the annual value of $174881.0 for FY2024, which is 2442.62% up from last year.
  • INVO Fertility's Receivables amounted to $274200.0 in Q3 2025, which was up 667.14% from $242255.0 recorded in Q2 2025.
  • In the past 5 years, INVO Fertility's Receivables ranged from a high of $807811.0 in Q1 2021 and a low of $47869.0 during Q2 2021
  • Moreover, its 5-year median value for Receivables was $116781.0 (2023), whereas its average is $168870.1.
  • Its Receivables has fluctuated over the past 5 years, first surged by 2173863.21% in 2021, then crashed by 9273.1% in 2022.
  • INVO Fertility's Receivables (Quarter) stood at $50470.0 in 2021, then surged by 52.86% to $77149.0 in 2022, then soared by 82.18% to $140550.0 in 2023, then increased by 24.43% to $174881.0 in 2024, then soared by 56.79% to $274200.0 in 2025.
  • Its Receivables stands at $274200.0 for Q3 2025, versus $242255.0 for Q2 2025 and $173614.0 for Q1 2025.